UroGen Pharma: Targeting Profits In 2027

Group 1 - The biotech sector presents numerous attractive covered call opportunities, particularly for investors who can identify the right equities to target [1] - Option premiums in the biotech sector are generally lucrative, and many stocks in this sector offer good liquidity [1] - The Biotech Forum provides a platform for discussions on solid covered call opportunities related to selected biotech stocks [1] Group 2 - UroGen Pharma Ltd. (NASDAQ: URGN) is highlighted as a small-cap biotech company, with renewed focus since the last article published in August of the previous year [2] - The Biotech Forum, led by Bret, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat for trade discussions and weekly research updates [2]